3-(3,5-二甲基异恶唑-4-基)丙-1-胺 | 771572-98-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-(3,5-二甲基异恶唑-4-基)丙-1-胺
• 中文别名: 3-(3,5-二甲基异恶唑-4-基)丙-1-胺HCL0.4H2O；3-(3,5-二甲基异噁唑-4-基)-1-丙胺
• 英文名称: 3,5-dimethyl-4-isoxazolepropanamine
• 英文别名: 3-(3,5-Dimethylisoxazol-4-YL)propan-1-amine；3-(3,5-dimethyl-1,2-oxazol-4-yl)propan-1-amine
• CAS: 771572-98-6
• 化学式: C₈H₁₄N₂O
• mdl: MFCD06213632
• 分子量: 154.212
• InChiKey: UUEBWEMWWZLONV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-(3,5-二甲基异恶唑-4-基)丙-1-胺 在 [Ir(dF(CF₃)ppy)₂(dtbbpy)](PF₆) 、 叠氮化四丁基铵 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 44.0h， 生成 (RS)-5-(2-(3,5-dimethylisoxazol-4-yl)ethyl)pyrrolidin-2-one
  参考文献：
  名称：

  通过未掩蔽的伯胺的 CH 烷基化光催化 α-叔胺合成。

  摘要：

  长期以来，通过 C-H 官能化实现 α,α,α-三取代（α-叔）伯胺的实用催化进入一直被认为是合成工具箱中的一个关键空白。我们报告了一个简单且可扩展的解决方案，不需要对氨基进行任何原位保护，并以 100% 的原子经济性进行。我们的策略使用有机光催化剂与叠氮离子结合作为氢原子转移（HAT）催化剂，提供了α-叔胺或其相应的γ-内酰胺的直接合成。我们预计这种方法将激发有机合成中取代胺衍生物的新逆合成断开，特别是对于具有挑战性的 α-叔伯胺。

  DOI：

  10.1002/anie.202005294

文献信息

• Direct α-alkylation of primary aliphatic amines enabled by CO2 and electrostatics
  作者：Juntao Ye、Indrek Kalvet、Franziska Schoenebeck、Tomislav Rovis

  DOI：10.1038/s41557-018-0085-9

  日期：2018.10

  Primary aliphatic amines are important building blocks in organic synthesis due to the presence of a synthetically versatile NH2 group. N-functionalization of primary amines is well established, but selective C-functionalization of unprotected primary amines remains challenging. Here, we report the use of CO2 as an activator for the direct transformation of abundant primary aliphatic amines into valuable

  由于存在合成用途广泛的NH 2基团，伯脂肪族伯胺是有机合成中的重要组成部分。伯胺的N-官能化是公认的，但是未保护的伯胺的选择性C-官能化仍然具有挑战性。在这里，我们报道了在光氧化还原和氢原子转移（HAT）催化下，CO 2作为活化剂用于将大量的初级脂肪族胺直接转化为有价值的γ-内酰胺的方法。实验和计算研究表明，CO 2不仅可以抑制不想要的N伯胺的-烷基化反应，但也可以通过原位产生的带负电的氨基甲酸酯和带正电的奎宁环鎓自由基之间的静电加速相互作用来促进选择性分子间HAT。这种静电吸引力压倒了固有的键解离能，这表明HAT应该无选择地发生。我们预期我们的发现将为HAT反应中的胺官能化以及选择性控制开辟新途径。
• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140243292A1

  公开（公告）日：2014-08-28

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色烯-6-氧基)-噻唑，其中Ar，R2，R3和R4如权利要求所定义。公式I化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器亚型1（NCX1）的抑制剂，并适用于治疗细胞内钙离子稳态受到干扰的多种疾病，如心律失常，心力衰竭和中风。本发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的制药组合物。
• Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
  申请人：SANOFI

  公开号：EP2567958B1

  公开（公告）日：2014-10-29
• SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20170037042A1

  公开（公告）日：2017-02-09

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.